Dramatic response to trastuzumab-deruxtecan in metastatic HER2-overexpressing vulvar extramammary Paget's disease: A case report
Myrtille Thomas, Mojgan Devouassoux-Shisheboran, Jonathan Lopez, Pierre Descargues, Witold Gertych, Ionela Caraivan, Benoit You, Julien Péron · 2026
Read Dramatic response to trastuzumab-deruxtecan in metastatic HER2-overexpressing vulvar extramammary Paget's disease: A case report by Myrtille Thomas, Mojgan Devouassoux-Shisheboran, Jonathan Lopez, Pierre Descargues, Witold Gertych, Ionela Caraivan, Benoit You, Julien Péron (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13627818.txt.
Description
Myrtille Thomas and co-authors report a striking response to a targeted drug in a rare skin cancer that had spread, in a 2026 case report. The cancer is vulvar extramammary Paget's disease, a slow skin malignancy that can turn invasive and metastasize. Tests showed this patient's tumor carried heavy amounts of HER2, a growth signal protein, with extra copies of its gene.
The cancer had already pushed through local treatment, surgery, radiation, and a HER2 antibody paired with chemotherapy. The team then gave trastuzumab-deruxtecan, an antibody that ferries a cell-killing drug straight to HER2-bearing cells, as an off-label second-line therapy. Tumors shrank markedly, both in the body and in the brain, and side effects stayed acceptable. The authors argue that such antibody-drug pairs deserve a place in treating HER2-positive cases of this disease once standard options run out.
Catalog record
| CREATOR | Myrtille Thomas, Mojgan Devouassoux-Shisheboran, Jonathan Lopez, Pierre Descargues, Witold Gertych, Ionela Caraivan, Benoit You, Julien Péron |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 11 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |